Axonics, Inc. Common Stock
AXNX
AXNX was delisted on the 14th of November, 2024.
235 hedge funds and large institutions have $3.12B invested in Axonics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 86 increasing their positions, 83 reducing their positions, and 31 closing their positions.
19% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 31
2% more funds holding
Funds holding: 230 → 235 (+5)
8% more call options, than puts
Call options by funds: $2.02M | Put options by funds: $1.86M
4% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 83
9% less capital invested
Capital invested by funds: $3.44B → $3.12B (-$315M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$52.4M |
| 2 |
Millennium Management
New York
|
+$38.1M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$36.4M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$30.6M |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$27.4M |
Top Sellers
AXNX Hedge Fund Activity: Q4 2022 in Review
235 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Axonics, Inc. Common Stock (AXNX) for Q4 2022, worth a combined $3.12B — down 9.2% from $3.44B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new AXNX positions and 31 closed out — a net gain of 6 holders — while 86 added to existing stakes and 83 trimmed.
The largest buyer was Vanguard Group, adding an estimated $52.4M. The largest seller was Ameriprise, cutting an estimated $63.2M.
- 235 institutional investors held Axonics, Inc. Common Stock (AXNX) as of Q4 2022, up from 230 in Q3 2022.
- Funds reported $3.12B of Axonics, Inc. Common Stock stock for Q4 2022, down 9.2% quarter-over-quarter.
- 37 funds opened new Axonics, Inc. Common Stock positions in Q4 2022 and 31 closed out, a net change of +6 holders.
- The largest Axonics, Inc. Common Stock buyer in Q4 2022 was Vanguard Group, an estimated $52.4M added.
- The largest Axonics, Inc. Common Stock seller in Q4 2022 was Ameriprise, an estimated $63.2M sold.
Based on aggregated 13F filings for Q4 2022.